tbuckley/cabot-search huggingface dataset:
Brucella Infections in Animals and Man: Methods of Laboratory Diagnosis
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hakimpara kites
Authors: James W. Girardy
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ON ARTIFICIAL TEETH.
Journal: JAMA (1894)

A writer in<i>Les Noveaux Remedies</i>for Sept. 8, 1894, says that "the teeth of the Americans are without doubt the worst in the world." "Also," says this most interesting person, "this eminently practical people have long since renounced the employment of the inferior products furnished by nature, for their substitute, artificial teeth." The writer then produces some statistics to show that some 8,000,000 false teeth have been sold in the last year. He also cites the statistics of M.Max de Nansouty, who has made a calculation to show the number of pounds of gold used in filling teeth in the United States. This amount, he asserts, is not less than 800 kilograms which represents about 2,500,000 francs. All this precious metal we are told, "is buried with the Yankees when they die," and on this assertion thisMartinus Scriblerussplutters, "supposing that this continues during some hundreds of
MOB LAW IN COLORADO.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Whooping cough and pertussis vaccination.
Journal: BMJ (1983)

have appeared recently, however, including our own.1A 25 year old nulliparous woman presented with generalised peritonitis and watery diarrhoea.She had had a copper 7 (Gravigard) device inserted two weeks previously.There was no gynaecological history and no vaginal discharge.The intrauterine contraceptive device was removed, and a high vaginal swab was taken.The pelvic organs could not be assessed because of tenderness.At laparotomy thin pus was found throughout the abdomen, but no source could be identified.Streptococcus pneumoniae was cultured from both the peritoneal fluid and the high vaginal swab.The patient made an uncomplicated recovery after drainage and a course of antibiotics.Although this case ended satisfactorily, delay in treatment might have been fatal.The presence of an intrauterine contraceptive
Malaria Therapy for Neurosyphilis
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased expression of mitochondrial cytochrome c and caspases 2, 3 and 7 in myocardium of dogs with chronic heart failure Sudhish Mishra, Ramesh C. Gupta, Victor G. Sharov, Takayuki Mishima, Anastassia Todor, George Suzuki, Sidney Goldstein, Hani N. Sabbah. Henry Ford Health System, Detroit, MI
Journal: Journal of the American College of Cardiology (2001)
SOME EFFECTS OF MODERATE PHYSICAL TRAINING
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
767. A Phase I/II Clinical Trial of Immunotherapy for CD19+ B Cell Malignancies With Defined Composition of CD4+ and CD8+ Central Memory T Cells Lentivirally Engineered To Express a CD19-Specific Chimeric Antigen Receptor Cameron J. Turtle, 1 David G. Maloney, 1 David M. Shank, 1 Daniel A. Sommermeyer, 1 Michael Hudecek, 1 Carolina Berger, 1 Jason
Journal: Molecular Therapy (2014)
Discovering adverse drug reactions
Authors: L. Lasagna
Journal: JAMA (1983)

When a new drug is marketed, one can be sure that not everything (good or bad) about the drug is known. There are always some surprises in store. Sometimes they are pleasant surprises. When lidocaine was introduced as a local anesthetic, who would have dreamed that it would one day become a drug of choice for terminating cardiac arrhythmias? Diazepam used to carry labeling that its use was hazardous to epileptics; it went on to be recognized as a treatment for status epilepticus. Probenecid was first used to augment the effects of penicillin by preventing the tubular secretion of the latter drug; today it is useful as a uricosuric agent in the treatment of gout. Aspirin, first marketed as a simple analgesic, is now not only a major drug for treating arthritis but can prevent vascular thrombosis. These are just a few of the many examples one could cite. The
Errors in Figure 3
Authors: Steven Narod, Vasily Giannakeas, Victoria Sopik
Journal: JAMA Oncology (2020)

Yong Xia, MD; Jun Li, MD; Guanghua Liu, MD; Kui Wang, MD; Guojun Qian, MD; Zhenhua Lu, MD; Tian Yang, MD; Zhenlin Yan, MD; Zhengqing Lei, MD; Anfeng Si, MD; Xuying Wan, MD; Han Zhang, MD; Chunfang Gao, MD; Zhangjun Cheng, MD; Timothy M Pawlik, MD, PhD; Hongyang Wang, MD, PhD; Wan Yee Lau, MD, FRCS; Mengchao Wu, MD; Feng Shen, MD, PhD
Treatments of homosexuality in Britain since the 1950s—an oral history: the experience of patients
Authors: Glenn Smith, Annie Bartlett, Michael King
Journal: BMJ (2004)

<h3>Abstract</h3> <b>Objectives</b> To investigate the circumstances since the 1950s in which people who were attracted to members of the same sex received treatments to change their sexual orientation, the referral pathway and the process of therapy, and its aftermath. <b>Design</b> A nationwide study based on qualitative interviews. <b>Participants</b> 29 people who had received treatments to change their sexual orientation in the United Kingdom and two relatives of former patients. <b>Results</b> Most participants had been distressed by their attraction to their own sex and people in whom they confided thought they needed treatment. Although some participants chose to undergo treatments instead of imprisonment or were encouraged through some form of medical coercion, most were responding to complex personal and social pressures that discouraged any expression of their sexuality. While many participants found happiness in same sex relationships after their treatment, most were left feeling emotionally distressed to some degree. <b>Conclusion</b> The definition of same sex attraction as an illness and the development of treatments to eradicate such attraction have had a negative long term impact on individuals.
Abstract 3626: Develop novel nanoparticle formulations of disulfiram copper for cancer therapy
Authors: Wu Chen, Wen Yang, Landon F. Stewart, David T. Coombs, Jianzhong Shen, Pengyu Chen, Feng LI
Journal: Cancer Research (2019)

Abstract Despite remarkable progress in cancer treatment, drug resistance remains a significant issue for prostate cancer, breast cancer, and others. Disulfiram (DSF), an alcohol-aversion drug, has been repurposed for cancer treatment and overcome drug resistance. DSF and copper ions form a copper diethyldithiocarbamate (Cu-DSF) complex which has a potent anticancer activity. However, the poor aqueous solubility of Cu-DSF creates a significant formulation challenge, and there is no formulation available for clinical use. We developed a Stabilized Metal Ion Ligand Nanocomplex (SMILE) technology to prepare Cu-DSF nanoparticle (NP) formulations where in situ formed DSF-Cu NPs were stabilized by an optimal amount of stabilizers (e.g. poly(ethylene glycol)-poly(lactide)). The SMILE technology involves a novel formulation design and an innovative preparation process using a 3D-printed microfluidic device. After optimizing the protocol, we can prepare Cu-DSF NPs with size in the sub-100 nm range which are suitable for intravenous injection and can target solid tumors through enhanced permeability and retention (EPR) effects. Cu-DSF NPs prepared with SMILE method showed high drug loading efficiency (above 90%) and high drug concentration (at least 2 mg/mL). The drug concentration of Cu-DSF NPs developed in our study was much higher than those in micelle NP formulations prepared with the classical film-dispersion method. Since we used generally recognized as safe (GRAS) excipients approved by the US Food and Drug Administration (FDA) or other excipients with well-recognized safety profiles, the developed NP formulations will have less regulatory hurdle for FDA approval. Because of the novel preparation process and unique formulation design, the SMILE technology can produce Cu-DSF NPs on a large scale and thus paved the way for its mass production and commercialization. We also determined the anticancer effects of Cu-DSF NPs with multiple assays including MTT assay, colony-forming assay, calcein-AM/propidium iodide staining, and others. Cu-DSF NPs showed excellent anticancer activity against various prostate cancer and breast cancer cells as well as drug-resistant cancer cells. In summary, we developed a novel SMILE method to prepare Cu-DSF NP formulations which could address drug delivery and formulation challenges of DSF-based chemotherapy and facilitate the clinical translation. Citation Format: Wu Chen, Wen Yang, Landon F. Stewart, David T. Coombs, Jianzhong Shen, Pengyu Chen, Feng LI. Develop novel nanoparticle formulations of disulfiram copper for cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3626.
Books in Brief
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Michael Ross, P Coates, Naveh-Many Tally, Justin Silver, Mark Marshall, Craig Langman, M Stokes, Vivette D'agati, Frederik Persson, Rikke Borg, Gary Chan, Sydney Tang, Janani Rangaswami, Roy Mathew, Peter Mccullough, Kamel Kamel, Martin Schreiber, Mitchell Halperin
Journal: Kidney International (2017)
The Human Homolog of the QKI Gene Affected in the Severe Dysmyelination “Quaking” Mouse Phenotype: Downregulated in Multiple Brain Regions in Schizophrenia
Authors: Vahram Haroutunian
Journal: American Journal of Psychiatry (2006)

Objective: The authors sought to understand the origins of oligodendrocyte/myelin gene expression abnormalities in the brains of persons with schizophrenia. Method: Twelve cortical regions (Brodmann’s areas 8, 10, 44, 46, 23/31, 24/32, 20, 21, 22, 36/28, 7, and 17) and three noncortical regions (caudate, hippocampus, and putamen) of 16 elderly schizophrenia patients and 14 matched comparison subjects were examined using 450 separate microarrays. The mRNA levels of QKI and its isoforms were then measured in a larger cohort by using quantitative real-time polymerase chain reaction (qPCR) in the cingulate cortex of schizophrenia subjects and matched comparison subjects. Results: Expression of QKI mRNA was decreased in seven cortical regions and the hippocampus in the schizophrenia subjects. QKI gene expression deficits detected by microarray were validated by qPCR in the cingulate cortex, where the expression of isoforms QKI-5, QKI-6, and QKI-7 were profoundly perturbed in schizophrenia. Conclusions: Since QKI plays a fundamental role in oligodendrocyte differentiation and in myelination, its underexpression may be pivotal to, and upstream of, other myelin-associated gene expression abnormalities in schizophrenia. Given the role of QKI in determination of oligodendrocyte fate, these results not only confirm oligodendrocyte-related gene expression abnormalities in schizophrenia but suggest that the physiology of glial progenitor cells may be altered in schizophrenia.
Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancers
Authors: Rebecca E. Schweppe, Anna A. Kerege, Jena D. French, Vibha Sharma, Rachel L. Grzywa, Bryan R. Haugen
Journal: Endocrine Reviews (2009)

Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC). The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC. PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays. FAK and phospho-FAK levels were analyzed in cell lines as well as in PTC tumor samples. AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal levels of phospho-Src. Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity. We further showed that pY861-FAK phosphorylation is Src-dependent. Sensitivity to AZD0530 was confirmed using a preclinical three-dimensional culture model. Phospho-ERK1/2 was not affected by AZD0530, indicating that Src signaling does not require MAPK. Finally, FAK and pY861-FAK were expressed in 10 of 10 and five of 10 PTC tumors, respectively. Inhibition of the Src-FAK complex represents a promising therapeutic strategy for patients with advanced thyroid cancer, and phospho-FAK represents a potential biomarker for response.
Prediction of factors affecting clinical trial accrual at Cancer Therapy and Research Center, San Antonio.
Authors: Praveena Iruku
Journal: Journal of Clinical Oncology (2017)

e18207 Background: Oncology is a very rapidly emerging science with need for more investigational drugs. It is highly essential to accrue patients into clinical trials to develop new drugs. According to the available data, about 38 % of the CTEP/NCI supporting oncology trials close due to inadequate accrual. We here by present a retrospective analysis of factors which affect clinical trial accrual in our institution. Methods: Eligible studies included treatment and supportive care intervention studies either open or closed to accrual between 09/1999 and 012/2015 at our center. Data abstracted includes coordinating group, sponsor type, presence of competing trials, trial phase, disease category, single institutional study, author, primary purpose of the study, interventional modality, targeted therapy, advanced disease, randomization, presence of placebo, rare cancer category and new investigational agents. Successful clinical trial accrual was defined as accruing 4 or more patients. Statistical analysis was performed in the statistic software R (R Foundation for Statistical Computing, Vienna, Austria). We used Chi-square test and Fisher’s exact test. The significance level was set to alpha = 0.05. Results: Retrospective univariate analysis at our institution showed that the variables significantly associated with clinical accrual are Authored by principal investigator, type of sponsor, phase of the trial and number of interventions in the study. Using a random forest model with the above mentioned predictors, we computed an AUC of 64.1 % . We have also developed a histogram of predictions which has identified atleast 5 studies with an 80% failure probability to accrue. Conclusions: Clinical trial accrual is absolutely necessary for development of investigational drugs and progress of research in Hematology/Oncology especially with the rise in incidence of many malignancies. We have identified a few factors that may impact accrual in our institution, and we propose to prospectively validate it in our future endeavor. The major limitations of our study are its retrospective nature and being a single site analysis.
Control of sexually transmitted chlamydial infections
Authors: H. H. Handsfield
Journal: JAMA (1987)

The recorded history of sexually transmitted<i>Chlamydia trachomatis</i>infections is brief; for example, reliable documentation that<i>C trachomatis</i>causes nongonococcal urethritis in men and general acceptance that nongonococcal urethritis is a sexually transmitted infection is barely 15 years old. During the 1970s and into the 1980s, the clinical spectrum of chlamydial infections was defined, and numerous studies demonstrated substantial—in some cases extraordinary— prevalences of infection in sexually active populations, especially young women. As a major cause of acute salpingitis, of female infertility and ectopic pregnancy due to scarring of the fallopian tubes (often in the absence of prior overt salpingitis), and of conjunctivitis and pneumonia in infants born to infected mothers, chlamydial infections have emerged as one of the most important women's health problems. Measures to control the chlamydia epidemic have been proposed since the early 1970s, but widespread acceptance that such measures are warranted came only in the mid-1980s,